Cancer Family
Malignant Neoplasm
CI-CAN-00000025CAExplore in graph →
20,116 active trials259 approved drugs3,741 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000025CAExplore in graph →
Clinical trials
90,685 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (11,163)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07848854 | Trop2-Targeted NIR-II Fluorescent Probe for Identifying Bladder Cancer in Ex Vivo Bladder Samples | recruiting | Phase 2 | 30 | Yunnan Cancer HospitalOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07849231 | Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Mutant Calreticulin Targeted Antibodies in CALR-mutant Myeloproliferative Neoplasms(CLARITY-101) | recruiting | Phase 1 | 250 | Damora TherapeuticsINDUSTRY | 1 | Sep 30, 2026 |
| clinicaltrials |
| NCT07849608 | Silent Evaluation of DeepTRG for Assessing Tumor Response After Preoperative Treatment in Stomach and Gastroesophageal Junction Cancer | recruiting | — | 200 | Qun ZhaoOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07850284 | SMS-Based Remote Symptom Monitoring for Patients With Plasma Cell Disorders | recruiting | — | 150 | Mayo ClinicOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07850791 | A Prospective Study of Sacituzumab Tirumotecan Plus Pembrolizumab for Advanced Biliary Tract Cancer | recruiting | Phase 2 | 38 | Haitao Zhao, MDOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT01492972 | Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer | recruiting | Phase 3 | 192 | Proton Collaborative GroupNETWORK | 1 | Sep 29, 2026 | clinicaltrials |
| NCT01766297 | Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer | recruiting | Phase 2 | 132 | Proton Collaborative GroupNETWORK | 1 | Sep 29, 2026 | clinicaltrials |
| NCT02598349 | Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas | recruiting | Phase 2 | 60 | Proton Collaborative GroupNETWORK | 1 | Sep 29, 2026 | clinicaltrials |
| NCT03739814 | Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia | recruiting | Phase 2 | 84 | National Cancer Institute (NCI)NIH | 2 | Sep 29, 2026 | clinicaltrials |
| NCT03802695 | A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies | recruiting | Phase 1 | 300 | Orca Biosystems, Inc.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04085900 | Screening Nasopharyngeal Carcinoma With EBV Associated Biomarkers in Zhongshan City | recruiting | — | 40,000 | Zhongshan People's Hospital, Guangdong, ChinaOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04181060 | Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer | recruiting | Phase 3 | 300 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04616560 | Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor | recruiting | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04628767 | Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer | recruiting | Phase 2 / Phase 3 | 131 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04912739 | Targeted Health Dialogues in Primary Care | recruiting | — | 18,000 | Region SkaneOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04981509 | Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer | recruiting | Phase 2 | 65 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05051722 | Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer(ECHO) | recruiting | — | 3,110 | Mayo ClinicOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05256225 | Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma | recruiting | Phase 3 | 360 | National Cancer Institute (NCI)NIH | 3 | Sep 29, 2026 | clinicaltrials |
| NCT05287451 | Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study | recruiting | N/A | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05304208 | dENdritic Cell Therapy Combined With SURgEry in Mesothelioma(ENSURE) | recruiting | Phase 1 | 16 | Erasmus Medical CenterOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05564377 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | recruiting | Phase 2 | 2,900 | National Cancer Institute (NCI)NIH | 2 | Sep 29, 2026 | clinicaltrials |
| NCT05611034 | In Vivo Lung Perfusion (IVLP) for Colorectal Cancer Metastatic to Lung | recruiting | Phase 1 | 10 | University Health Network, TorontoOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05803382 | Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers | recruiting | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05856773 | Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy(COMPRO) | recruiting | Phase 3 | 276 | Proton Collaborative GroupNETWORK | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05874921 | uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto(uTRACT) | recruiting | — | 450 | UroGen Pharma Ltd.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05877599 | A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation | recruiting | Phase 1 | 45 | AstraZenecaINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05902169 | Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM(SONOBIRD) | recruiting | Phase 3 | 560 | CarTheraINDUSTRY | 11 | Sep 29, 2026 | clinicaltrials |
| NCT05952024 | Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL(ACRUE) | recruiting | Phase 2 | 80 | AstraZenecaINDUSTRY | 5 | Sep 29, 2026 | clinicaltrials |
| NCT06046794 | Efficacy of First-Line Gemcitabine Chemotherapy in GemCore+ Metastatic Pancreatic Adenocarcinoma Patients(GemSign-01) | recruiting | N/A | 100 | Institut Paoli-CalmettesOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06203600 | Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial | recruiting | Phase 2 / Phase 3 | 224 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06309225 | Dose Adjusted Chemoradiotherapy in HPV-Associated Oropharynx Cancer of the Elderly((DACHOC-E)) | recruiting | N/A | 20 | Omar MahmoudOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06337318 | Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma | recruiting | Phase 3 | 600 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06377540 | MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma | recruiting | Phase 2 | 28 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06466434 | Prebiotic Food-enriched Diet (PreFED) to Enhance the Microbiome and Response to First-line Immunotherapy in Unresectable Melanoma | recruiting | N/A | 75 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06479811 | [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers | recruiting | Phase 1 | 120 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06498635 | Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial | recruiting | Phase 3 | 306 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06498648 | Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma | recruiting | Phase 1 / Phase 2 | 74 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06524583 | Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour(L-UteCIN) | recruiting | Phase 2 | 198 | UNICANCEROTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06541210 | Building Community Living Labs in Black Communities to Advance Prostate Health Equity and Reduce Prostate Cancer Disparities in Black Men(CoLLab) | recruiting | N/A | 250 | Mayo ClinicOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06605664 | Hyperpolarized 13C-MRI in Patients With Hepatocellular Carcinoma Undergoing Radiotherapy, Atezolizumab, and Bevacizumab | recruiting | Phase 2 | 45 | Chang Gung Memorial HospitalOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06627712 | SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC | recruiting | Phase 3 | 318 | West China HospitalOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06637150 | Dalpicilib-Enhanced vs. Standard Endocrine Therapy in ER+ HER2- Early Breast Cancer | recruiting | Phase 3 | 1,388 | Fudan UniversityOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06649812 | Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma | recruiting | Phase 2 | 120 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06738303 | Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer(CATCH-177) | recruiting | Phase 2 | 44 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06763341 | A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 12 | City of Hope Medical CenterOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06799065 | First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer | recruiting | Phase 1 / Phase 2 | 218 | Accent TherapeuticsINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06865664 | FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma | recruiting | Phase 1 | 50 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
Data updated 3 hours agoSource updated Sep 30, 2026source: clinicaltrials